drugset / Trial / NCT00002427

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427

Phase 1 Completed 225 enrolled Research Institute for Genetic and Human Therapy
FactorialTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of 9 doses of HU in order to find the best dose of HU to use with ddI and d4T in fighting HIV infection. HU plus ddI plus d4T appears to be a suitable anti-HIV drug combination for long-term control of HIV. This combination can sharply decrease viral load (level of HIV in the body) with few side effects, making it easy to take.

Timeline

Start
1999-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified
Background Didanosine Small molecule
Background Stavudine Other / unclassified